US 11,944,643 B2
Universal anti-CD22 chimeric antigen receptor engineered immune cells
Julianne Smith, New York, NY (US); Philippe Duchateau, Draveil (FR); and Murielle Derrien, Paris (FR)
Assigned to CELLECTIS SA, Paris (FR)
Appl. No. 16/498,899
Filed by CELLECTIS SA, Paris (FR)
PCT Filed Mar. 30, 2018, PCT No. PCT/EP2018/058367
§ 371(c)(1), (2) Date Sep. 27, 2019,
PCT Pub. No. WO2018/178377, PCT Pub. Date Oct. 4, 2018.
Claims priority of application No. PA201770239 (DK), filed on Mar. 31, 2017; application No. PA201770240 (DK), filed on Mar. 31, 2017; application No. PA201770542 (DK), filed on Jun. 30, 2017; and application No. PCT/EP2017/076800 (WO), filed on Oct. 19, 2017.
Prior Publication US 2021/0161954 A1, Jun. 3, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/17 (2015.01); A61K 31/365 (2006.01); A61K 39/395 (2006.01); A61P 35/02 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01)
CPC A61K 35/17 (2013.01) [A61K 31/365 (2013.01); A61K 39/39558 (2013.01); A61P 35/02 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 2317/34 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01)] 12 Claims
 
1. An engineered human Universal Chimeric Antigen Receptor T Cell specific for CD22 (UCART22) comprising a Chimeric Antigen Receptor specific for CD22 (anti-CD22 CAR), and a safety switch;
wherein said anti-CD22 CAR comprises:
(i) at least one extracellular domain comprising a hinge domain from CD8alpha, and an antigen binding domain specific for CD22;
(ii) a transmembrane domain from CD8alpha; and
(iii) an intracellular signaling domain;
wherein said anti-CD22 CAR comprises a polypeptide sequence having at least 80% sequence identity with a full-length sequence of SEQ ID NO: 15; and
wherein said safety switch comprises:
(i) an RQR8 region linked to the anti-CD22 CAR by a cleavable peptide 2A linker, wherein the RQR8 region comprises the sequence of SEQ ID NO: 60;
(ii) at least two rituximab mAb-specific epitopes located between the antigen binding domain and the hinge domain of the anti-CD22 CAR;
(iii) three rituximab mAb-specific epitopes linked to the anti-CD22 CAR; or
(iv) three rituximab mAb-specific epitopes and one QBEND-10 mAb-specific epitope linked to the anti-CD22 CAR.